Evidence map›Paper›PMID 42200295›Full record

ArticleNucleic acids research2026

Bacterial type II topoisomerases cleave DNA in a species-specific manner.

Ian L Morgan, Jeffrey Y Jian, Jillian F Armenia, Neil Osheroff, Keir C Neuman

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Ian L MorganNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, United States.ORCID 0000-0001-6772-6883
Jeffrey Y JianDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, United States.
Jillian F ArmeniaDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, United States.ORCID 0000-0001-5954-0763
Neil OsheroffDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, United States.ORCID 0000-0002-2550-4884
Keir C NeumanNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, United States.ORCID 0000-0002-0863-5671

Funding

Single-molecule measurements of DNA topology and topoisomerasesZIAHL001056 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI NEUMAN, KEIR · 2009 to 2025
$22.6M
Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted AntibacterialsR01AI170546 · NIAID · VANDERBILT UNIVERSITY · PI NEIL OSHEROFF · 2023 to 2026
$2.7M
Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted AgentsR01GM126363 · NIGMS · VANDERBILT UNIVERSITY · PI OSHEROFF, NEIL · 2018 to 2025
$2.6M
NHLBI NIH HHSNHLBI NIH HHS ZIAHL001056NIGMS NIH HHS 1FI2GM142536NIH HHS 1ZIAHL001056NIH HHS R01 AI170546NIH HHS R01 GM126363
6 · The paper itself

Abstract

The type II topoisomerases, gyrase and topoisomerase IV, are ubiquitous enzymes in bacteria that help regulate DNA topology and are the molecular targets of fluoroquinolone antibacterials. As part of their catalytic mechanism, these enzymes transiently cleave DNA in a sequence-dependent manner. Determining the extent to which various factors influence the sequence-dependent cleavage of these enzymes, particularly across bacterial species, could help reveal important insights into their physiological functions and guide the development of new, more effective antibacterials. Here, we used our recently developed SHAN-seq method to map and compare the DNA cleavage site preferences of gyrases and topoisomerase IVs from three different pathogenic bacterial species, Escherichia coli, Bacillus anthracis, and Mycobacterium tuberculosis, in the presence of the fluoroquinolone, ciprofloxacin. We found that the enzymes' cleavage specificities vary across bacterial species, with DNA supercoil chirality, and in response to ciprofloxacin. Our findings suggest that subtle variations in the enzymes' catalytic core and C-terminal domains alter their cleavage site preferences, which could, in turn, influence their physiological activities and susceptibility to fluoroquinolone antibacterials.

Indexed as

DNA CleavageDNA GyraseDNA Topoisomerase IVAnti-Bacterial AgentsBacillus anthracisCatalytic DomainCiprofloxacinDNA, BacterialEscherichia coliMycobacterium tuberculosisSpecies SpecificitySubstrate SpecificityAnti-Bacterial AgentsCiprofloxacinDNA, BacterialDNA GyraseDNA Topoisomerase IV

Identifiers

PMID42200295
PMCPMC13213244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.